ストックスクリーナーアプリを入手
27.52
2.93%
-0.83
Apellis Pharmaceuticals Inc (APLS) 最新ニュース
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
High Growth Tech Stocks In The United States To Watch - Yahoo Finance
Layoff Tracker: Spotlight Goes Dark After Disappointing Preclinical Data for CRISPR Platform - BioSpace
Is Apellis Pharmaceuticals (APLS) One of the Most Oversold Healthcare Stocks to Buy Now? - Yahoo Finance
Sobi, Apellis Seek EMA Nod for Expanded Use of Aspaveli in Rare Kidney Diseases - Marketscreener.com
Apellis Pharmaceuticals, Sobi Say EMA Validated Indication Extension Application for Potential Kidney Disease Treatment - Marketscreener.com
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN - The Manila Times
APLS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Apellis Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ACCESS Newswire
Apellis Pharmaceuticals chief people officer sells shares worth $37,178 - MSN
10 Top Insider Stock Buys And Sells In January - Insider Monkey
Apellis Pharmaceuticals (APLS): Among Top Insider Stock Buys And Sells In January - Insider Monkey
Apellis stock jumps as rare kidney disease therapy succeeds in trial - MSN
Apellis Pharmaceuticals' chief people officer sells $53,275 in stock - MSN
Apellis Pharmaceuticals (APLS) to Release Earnings on Tuesday - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Short Interest Update - MarketBeat
HC Wainwright Reaffirms Buy Rating for Apellis Pharmaceuticals (NASDAQ:APLS) - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Mark Jeffrey Delong Sells 363 Shares - MarketBeat
Savant Capital LLC Purchases 9,407 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Entropy Technologies LP Makes New Investment in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Bought by Banque Pictet & Cie SA - MarketBeat
Raymond James maintains Strong Buy on Apellis shares, target at $78 - MSN
Apellis Pharmaceuticals (NASDAQ:APLS investor one-year losses grow to 60% as the stock sheds US$248m this past week - Simply Wall St
(APLS) Investment Analysis and Advice - Stock Traders Daily
Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Apellis Pharmaceuticals to Hold Conference Call on Q4 and Full Year 2024 Financial Results - Nasdaq
Apellis Pharmaceuticals' chief business officer sells $10,359 in stock - MSN
Fierce Biotech Layoff Tracker 2025: Encoded trims 29% of team; Inventiva halves staff - Fierce Biotech
Raymond James maintains Strong Buy on Apellis shares, target at $78 By Investing.com - Investing.com South Africa
What 6 Analyst Ratings Have To Say About Apellis Pharmaceuticals - Benzinga
Apellis Pharmaceuticals (NASDAQ:APLS investor one-year losses grow to 58% as the stock sheds US$231m this past week - Yahoo Finance
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Apellis Pharmaceuticals' chief business officer sells $10,359 in stock By Investing.com - Investing.com UK
Apellis Pharmaceuticals Officer Sells Shares to Cover Taxes - TradingView
Piper Sandler maintains neutral on Apellis stock, $32 target - MSN
APLSApellis Pharmaceuticals Announces Closing of Offering of Convertible Senior Notes - br.ADVFN.com
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Addition... - br.ADVFN.com
Apellis Pharmaceuticals Reports Third Quarter 2019 Business Update and Financial Results - br.ADVFN.com
Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in ... - br.ADVFN.com
Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN - br.ADVFN.com
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - br.ADVFN.com
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):